Physician profile
John M Ogle
NPI 1376515304
$398.69
in general payments reported to CMS, 2019-2025
16 companies · $88.52 in 2025
The $88.52 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $27.00 · 2021: $61.06 · 2022: $15.95 · 2023: $50.63 · 2024: $32.00 · 2025: $88.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $171.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $51.17 | 2025 | Xt Cdx |
| Pfizer INC. | $40.22 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $36.52 | 2023-2024 | Qelbree, Qelbree |
| Corium, LLC | $32.80 | 2023 | Azstarys |
| Cranial Technologies, INC | $31.73 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.57 | 2019-2021 | |
| Tris Pharma INC | $26.36 | 2019-2020 | |
| Neos Therapeutics, LP | $20.40 | 2019 | |
| Abbvie INC. | $20.21 | 2019 | |
| Sanofi Pasteur INC. | $20.07 | 2025 | |
| Collegium Pharmaceutical, INC. | $17.28 | 2025 | Jornay Pm |
| Arbor Pharmaceuticals, INC. | $15.45 | 2019 | |
| Genentech USA, INC. | $15.32 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.24 | 2020 | |
| Merck Sharp & Dohme LLC | $13.31 | 2024 | Proquad, Pedvaxhib, Vaxelis |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ogle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.